An rna toolbox for cancer immunotherapy

Fernando Pastor, Pedro Berraondo, Iñaki Etxeberria, Josh Frederick, Ugur Sahin, Eli Gilboa, Ignacio Melero

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

| Cancer immunotherapy has revolutionized oncology practice. However, current protein and cell therapy tools used in cancer immunotherapy are far from perfect, and there is room for improvement regarding their efficacy and safety. RNA-based structures have diverse functions, ranging from gene expression and gene regulation to pro-inflammatory effects and the ability to specifically bind different molecules. These functions make them versatile tools that may advance cancer vaccines and immunomodulation, surpassing existing approaches. These technologies should not be considered as competitors of current immunotherapies but as partners in synergistic combinations and as a clear opportunity to reach more efficient and personalized results. RNA and RNA derivatives can be exploited therapeutically as a platform to encode protein sequences, provide innate pro-inflammatory signals to the immune system (such as those denoting viral infection), control the expression of other RNAs (including key immunosuppressive factors) post-transcriptionally and conform structural scaffoldings binding proteins that control immune cells by modifying their function. Nascent RNA immunotherapeutics include RNA vaccines encoding cancer neoantigens, mRNAs encoding immunomodulatory factors, viral RNA analogues, interference RNAs and protein-binding RNA aptamers. These approaches are already in early clinical development with promising safety and efficacy results.

Original languageEnglish (US)
Pages (from-to)751-767
Number of pages17
JournalNature Reviews Drug Discovery
Volume17
Issue number10
DOIs
StatePublished - Oct 1 2018

Fingerprint

Immunotherapy
RNA
Neoplasms
Cancer Vaccines
Nucleotide Aptamers
Safety
RNA-Binding Proteins
Immunomodulation
Viral RNA
Gene Expression Regulation
Virus Diseases
Immunosuppressive Agents
Infection Control
Cell- and Tissue-Based Therapy
RNA Interference
Immune System
Carrier Proteins
Proteins
Technology
Messenger RNA

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Pastor, F., Berraondo, P., Etxeberria, I., Frederick, J., Sahin, U., Gilboa, E., & Melero, I. (2018). An rna toolbox for cancer immunotherapy. Nature Reviews Drug Discovery, 17(10), 751-767. https://doi.org/10.1038/nrd.2018.132

An rna toolbox for cancer immunotherapy. / Pastor, Fernando; Berraondo, Pedro; Etxeberria, Iñaki; Frederick, Josh; Sahin, Ugur; Gilboa, Eli; Melero, Ignacio.

In: Nature Reviews Drug Discovery, Vol. 17, No. 10, 01.10.2018, p. 751-767.

Research output: Contribution to journalReview article

Pastor, F, Berraondo, P, Etxeberria, I, Frederick, J, Sahin, U, Gilboa, E & Melero, I 2018, 'An rna toolbox for cancer immunotherapy', Nature Reviews Drug Discovery, vol. 17, no. 10, pp. 751-767. https://doi.org/10.1038/nrd.2018.132
Pastor F, Berraondo P, Etxeberria I, Frederick J, Sahin U, Gilboa E et al. An rna toolbox for cancer immunotherapy. Nature Reviews Drug Discovery. 2018 Oct 1;17(10):751-767. https://doi.org/10.1038/nrd.2018.132
Pastor, Fernando ; Berraondo, Pedro ; Etxeberria, Iñaki ; Frederick, Josh ; Sahin, Ugur ; Gilboa, Eli ; Melero, Ignacio. / An rna toolbox for cancer immunotherapy. In: Nature Reviews Drug Discovery. 2018 ; Vol. 17, No. 10. pp. 751-767.
@article{a954cad943f148768d8befcbdac08ba9,
title = "An rna toolbox for cancer immunotherapy",
abstract = "| Cancer immunotherapy has revolutionized oncology practice. However, current protein and cell therapy tools used in cancer immunotherapy are far from perfect, and there is room for improvement regarding their efficacy and safety. RNA-based structures have diverse functions, ranging from gene expression and gene regulation to pro-inflammatory effects and the ability to specifically bind different molecules. These functions make them versatile tools that may advance cancer vaccines and immunomodulation, surpassing existing approaches. These technologies should not be considered as competitors of current immunotherapies but as partners in synergistic combinations and as a clear opportunity to reach more efficient and personalized results. RNA and RNA derivatives can be exploited therapeutically as a platform to encode protein sequences, provide innate pro-inflammatory signals to the immune system (such as those denoting viral infection), control the expression of other RNAs (including key immunosuppressive factors) post-transcriptionally and conform structural scaffoldings binding proteins that control immune cells by modifying their function. Nascent RNA immunotherapeutics include RNA vaccines encoding cancer neoantigens, mRNAs encoding immunomodulatory factors, viral RNA analogues, interference RNAs and protein-binding RNA aptamers. These approaches are already in early clinical development with promising safety and efficacy results.",
author = "Fernando Pastor and Pedro Berraondo and I{\~n}aki Etxeberria and Josh Frederick and Ugur Sahin and Eli Gilboa and Ignacio Melero",
year = "2018",
month = "10",
day = "1",
doi = "10.1038/nrd.2018.132",
language = "English (US)",
volume = "17",
pages = "751--767",
journal = "Nature Reviews Drug Discovery",
issn = "1474-1776",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - An rna toolbox for cancer immunotherapy

AU - Pastor, Fernando

AU - Berraondo, Pedro

AU - Etxeberria, Iñaki

AU - Frederick, Josh

AU - Sahin, Ugur

AU - Gilboa, Eli

AU - Melero, Ignacio

PY - 2018/10/1

Y1 - 2018/10/1

N2 - | Cancer immunotherapy has revolutionized oncology practice. However, current protein and cell therapy tools used in cancer immunotherapy are far from perfect, and there is room for improvement regarding their efficacy and safety. RNA-based structures have diverse functions, ranging from gene expression and gene regulation to pro-inflammatory effects and the ability to specifically bind different molecules. These functions make them versatile tools that may advance cancer vaccines and immunomodulation, surpassing existing approaches. These technologies should not be considered as competitors of current immunotherapies but as partners in synergistic combinations and as a clear opportunity to reach more efficient and personalized results. RNA and RNA derivatives can be exploited therapeutically as a platform to encode protein sequences, provide innate pro-inflammatory signals to the immune system (such as those denoting viral infection), control the expression of other RNAs (including key immunosuppressive factors) post-transcriptionally and conform structural scaffoldings binding proteins that control immune cells by modifying their function. Nascent RNA immunotherapeutics include RNA vaccines encoding cancer neoantigens, mRNAs encoding immunomodulatory factors, viral RNA analogues, interference RNAs and protein-binding RNA aptamers. These approaches are already in early clinical development with promising safety and efficacy results.

AB - | Cancer immunotherapy has revolutionized oncology practice. However, current protein and cell therapy tools used in cancer immunotherapy are far from perfect, and there is room for improvement regarding their efficacy and safety. RNA-based structures have diverse functions, ranging from gene expression and gene regulation to pro-inflammatory effects and the ability to specifically bind different molecules. These functions make them versatile tools that may advance cancer vaccines and immunomodulation, surpassing existing approaches. These technologies should not be considered as competitors of current immunotherapies but as partners in synergistic combinations and as a clear opportunity to reach more efficient and personalized results. RNA and RNA derivatives can be exploited therapeutically as a platform to encode protein sequences, provide innate pro-inflammatory signals to the immune system (such as those denoting viral infection), control the expression of other RNAs (including key immunosuppressive factors) post-transcriptionally and conform structural scaffoldings binding proteins that control immune cells by modifying their function. Nascent RNA immunotherapeutics include RNA vaccines encoding cancer neoantigens, mRNAs encoding immunomodulatory factors, viral RNA analogues, interference RNAs and protein-binding RNA aptamers. These approaches are already in early clinical development with promising safety and efficacy results.

UR - http://www.scopus.com/inward/record.url?scp=85054305618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054305618&partnerID=8YFLogxK

U2 - 10.1038/nrd.2018.132

DO - 10.1038/nrd.2018.132

M3 - Review article

C2 - 30190565

AN - SCOPUS:85054305618

VL - 17

SP - 751

EP - 767

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

SN - 1474-1776

IS - 10

ER -